Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov:148:109435.
doi: 10.1016/j.yebeh.2023.109435. Epub 2023 Sep 23.

The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?

Elinor Ben-Menachem  1 , Bettina Schmitz  2 , Reetta Kälviäinen  3 , Rhys H Thomas  4 , Pavel Klein  5
Affiliations
Free article
Review

The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?

Elinor Ben-Menachem et al. Epilepsy Behav. 2023 Nov.
Free article

Abstract

Despite the many therapeutic options for epilepsy available today, a third of patients still have poorly controlled epilepsy. Over the years, their transition through lines of treatment exposes them to increased risk of disease progression, mortality, morbidity, mental distress, and not least significantly impaired quality of life (QoL). The present review explores the multiple factors contributing to the impairment of health-related QoL in PWE-including both seizure-related and non seizure-related. The analysis aims to identify potential areas of intervention and strategies for a more holistic approach to epilepsy care and inform policy-makers and healthcare providers in their approach to this condition.

Keywords: Add-on; Burden of disease; Drug-resistant epilepsy (DRE); Focal onset seizures; Quality of life (QoL); Third generation antiseizure medications (ASMs).

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: EBM has received consulting fees/and or honoraria from UCB, Angelini, GW Pharma. BS has received speaker honoraria or consultancy fees from Angelini Pharma, Desitin, Eisai, Precisis, Sanofi, and UCB-Pharma.RK has received speaker fee/honoraria from Angelini Pharma, Eisai, Finnish IBE chapter, Omamedical, GW Pharmaceuticals, Marinus, Orion, Sandoz, Takeda, UCB Pharma; consulting fees from Orion; grants from Angelini Pharma. She covers the role of Neurocenter Finland, EAN Epilepsy Scientific Panel management Group, EpiCARE ERN executive group.PK has served as a consultant, advisory board member or speaker for Abbott, Angelini, Aquestive, Arvelle Therapeutics, Aucta Pharmaceuticals, Dr. Reddy’s, Eisai, Neurelis, Neurona, Paladin, SK Life Science, Sunovion, UCB Pharma, UNEEG, UniQure, is a member of the Medical Advisory Board of Stratus and of the Scientific Advisory Board of OB Pharma, is the CEO of PrevEp, Inc, and has received research support from CURE/Department of Defense and from the NIH/SBIR. TR has received unrestricted grants from Angelini and UNEEG, consulting fees from Angelini, Bial, Biocodex, Eisai, Jazz/GW Pharma, Neuraxpharm, Sanofi, Takeda, UCB Pharma, Zogenix, payment and honoraria from Angelini, Bial, Eisai, Jazz/GW Pharma, UCB Pharma, UNEEG, Zogenix.

References

Publication types

Substances